期刊
PLOS ONE
卷 8, 期 5, 页码 -出版社
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0063773
关键词
-
资金
- National Institute of Mental Health
- Yale Child Study Center Research Training Program
- National Institutes of Health [1K23MH091240-01]
- APIRE/Eli Lilly Psychiatric Research Fellowship
- AACAP/Eli Lilly Pilot Research Award
- Trichotillomania Learning Center
- National Alliance for Research on Schizophrenia and Depression (NARSAD) [UL1 RR024139]
- National Center for Research Resources
- National Institutes of Health
- NIH roadmap for Medical Research
- Department and Institute of Psychiatry of the University of Sao Paulo School of Medicine Hospital das Clinicas
- Brazil National Counsel of Technological and Scientific Development
Study Objectives: To investigate the efficacy of melatonin compared to placebo in improving sleep parameters in patients with primary sleep disorders. Design: PubMed was searched for randomized, placebo-controlled trials examining the effects of melatonin for the treatment of primary sleep disorders. Primary outcomes examined were improvement in sleep latency, sleep quality and total sleep time. Meta-regression was performed to examine the influence of dose and duration of melatonin on reported efficacy. Participants: Adults and children diagnosed with primary sleep disorders. Interventions: Melatonin compared to placebo. Results: Nineteen studies involving 1683 subjects were included in this meta-analysis. Melatonin demonstrated significant efficacy in reducing sleep latency (weighted mean difference (WMD) = 7.06 minutes [95% CI 4.37 to 9.75], Z = 5.15, p<0.001) and increasing total sleep time (WMD = 8.25 minutes [95% CI 1.74 to 14.75], Z = 2.48, p = 0.013). Trials with longer duration and using higher doses of melatonin demonstrated greater effects on decreasing sleep latency and increasing total sleep time. Overall sleep quality was significantly improved in subjects taking melatonin (standardized mean difference = 0.22 [95% CI: 0.12 to 0.32], Z = 4.52, p<0.001) compared to placebo. No significant effects of trial duration and melatonin dose were observed on sleep quality. Conclusion: This meta-analysis demonstrates that melatonin decreases sleep onset latency, increases total sleep time and improves overall sleep quality. The effects of melatonin on sleep are modest but do not appear to dissipate with continued melatonin use. Although the absolute benefit of melatonin compared to placebo is smaller than other pharmacological treatments for insomnia, melatonin may have a role in the treatment of insomnia given its relatively benign side-effect profile compared to these agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据